公开(公告)号：US20180057888A1

公开(公告)日：2018-03-01

申请号：US15557608

申请日：2016-03-08

Applicant: The Board of Regents of the University of Texas System

Inventor： David A. BOOTHMAN ,  Edward A. MOTEA ,  Praveen PATIDAR ,  Julio MORALES

IPC: C12Q1/68 ,  C12N15/113 ,  A61N5/10

CPC classification number: C12Q1/6886 ,  A61N5/10 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Y204/0203 ,  G01N33/574 ,  G01N2333/4703 ,  G01N2800/52 ,  G01N2800/56

Abstract: The present disclosure is directed to methods of detecting KUB5/HERA expression levels, copy number and mutation status, particularly in cancer cells. The methods permit physicians to tailor therapies to subject having certain genotypes/phenotypes, and to exclude therapies unlikely to be effective.

公开(公告)号：US20170342503A1

公开(公告)日：2017-11-30

申请号：US15602004

申请日：2017-05-22

Applicant: The Board of Regents of the University of Texas System

Inventor： David A. BOOTHMAN ,  Julio MORALES ,  Edward MOTEA ,  Praveen PATIDAR

IPC: C12Q1/68 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57415 ,  G01N33/57438

Abstract: The present disclosure is directed to methods of detecting XRN2 expression levels, copy number and mutation status, particularly in cancer cells. The methods permit physicians to tailor therapies to subject having certain genotypes/phenotypes, and to exclude therapies unlikely to be effective.